No abstract

No abstract

Introduction: The recommended treatment of grade 3 giant cell tumor of bone (grade 3 GCTB) aims to eliminate tumor and conserve limb with extended intralesional curettage. This treatment makes patients better function of bone and joint as usual. Even it can reduce postoperative complications and replace endoprosthesis. Still, there is limited information about the outcomes of surgical treatment and recurrence of the disease. This study aimed to evaluate the clinical outcomes and recurrence of grade 3 GCTB with extended intralesional curettage.

There remains a lack of consensus regarding the necessity of implant augmentation or fixation after intralesional curettage in giant cell tumor of bone (GCTB) around the knee. This study assessed whether cementation alone is effective and safe in GCTB with a non-fracture around the knee. We retrospectively examined clinical data from 14 GCTB patients treated from 2012 to 2022. Outcome parameters were Musculoskeletal Tumor Society (MSTS) score, postoperative fracture, metastases, recurrence and complications. Of the 14 GCTB cases examined, 10 were at the distal femur and four were at the proximal tibia. Mean patient age was 32 years, and follow-up time was 61 months. Mean tumor size was 61 × 79 × 50 mm, and MSTS score was 89.2%. There were no cases of postoperative fracture. Defect reconstruction with cementation alone may be strong enough to provide immediate stability and prevent postoperative fracture in GCTB around the knee.